Efficacy and safety of probucol plus telmisartan for type-2 diabetic nephropathy: a multicentre, prospective, randomised, double-blind, double-dummy, controlled trial.
Phase of Trial: Phase IV
Latest Information Update: 27 Sep 2013
At a glance
- Drugs Probucol (Primary) ; Telmisartan (Primary)
- Indications Diabetic nephropathies; Renal failure
- Focus Therapeutic Use
- 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 16 Oct 2012 Status changed from not yet recruiting to completed as reported by Chinese Clinical Trial Register.
- 21 May 2012 Planned end date changed from 1 Dec 2011 to 30 Jun 2012 as reported by Chinese Clinical Trial Register.